跳至主要内容
临床试验/CTRI/2023/06/054158
CTRI/2023/06/054158尚未招募3 期

A Comparative clinical study to evaluate the efficacy of Paarthadi Kwath along with Hridbasti and calcium channel blocker on Essential Hypertension

DPU Seed Money with letter no DPU1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年1月7日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
Patient showing relief from clinical sign and symptoms of essential hypertension.

研究概览

简要总结

A group of 20 patients will get Paarthadi Kwath along with Hridbasti for a period of 7 days. Another group of 20 patients will get Tab. Stamlo 2.5mg for 7 days. Data will be collected and compared.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
0.00 Day(s) 至 7.00 Day(s)(—)
性别
All

入选标准

  • 18-70 years of either gender.
  • Systolic Blood pressure less than 170mmHg more than or equal to 140mmHg.
  • Distolic Blood Pressure less thann or equal to 110mmHg and more than 90mmHg.
  • Hypertension Stage II according to JNC seventh report 2004.

排除标准

  • Patient that past history of atrial fibrillation, acute coronary syndrome ,myocardial infarction, stroke, right ventricular hypertrophy, left ventricular hypertrophy, severe arrhythmia in last 6 months.
  • Symptomatic patient with clinical feature of early heart failure.
  • Secondary hypertension.
  • Patient with concurrent serious hepatic dysfunction, renal dysfunction, uncontrolled pulmonary dysfunction.
  • Patient suffering with diabetes nephropathy.
  • Women who are pregnant, lactating or on estrogen replacement therapy.
  • Alcohol and Drug abusers.
  • Accelerated and maligant hypertension.

结局指标

主要结局

Patient showing relief from clinical sign and symptoms of essential hypertension.

时间窗: 0, 4 and 7 day

次要结局

  • To complete seven days treatment(0, 4 and 7 day)

研究者

发起方
DPU Seed Money with letter no DPU
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验